Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University and Monash Health, Locked Bag 29, Clayton, VIC 3168, Australia.
Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University and Monash Health, Locked Bag 29, Clayton, VIC 3168, Australia.
Trends Endocrinol Metab. 2019 Jul;30(7):467-478. doi: 10.1016/j.tem.2019.04.006. Epub 2019 May 31.
Polycystic ovary syndrome (PCOS) affects 8-13% of women. The Rotterdam diagnostic criteria include polycystic ovarian morphology (PCOM) on ultrasound, but given recognized challenges, serum anti-Müllerian hormone (AMH) is proposed as an alternative. To inform international PCOS guidelines, a systematic review was completed. Key identified gaps include large international studies in well-defined populations across the lifespan, clustering of AMH with PCOS features, relationships to long-term health outcomes, and improved quality, assay standardization, and sample handling, all needed to determine cut offs. Here we identify research priorities to address these gaps and enhance AMH utility in PCOS. Once issues are addressed, AMH levels could replace more costly and less accessible ultrasound in PCOS diagnosis.
多囊卵巢综合征（PCOS）影响 8-13%的女性。罗得岛诊断标准包括超声多囊卵巢形态（PCOM），但鉴于公认的挑战，血清抗缪勒管激素（AMH）被提议作为替代方法。为了为国际 PCOS 指南提供信息，完成了一项系统评价。主要确定的差距包括在整个生命周期内，在明确界定的人群中进行大型国际研究、AMH 与 PCOS 特征的聚类、与长期健康结果的关系，以及提高质量、检测标准化和样本处理，所有这些都需要确定截止值。在这里，我们确定了研究重点，以解决这些差距，并提高 AMH 在 PCOS 中的应用。一旦解决了这些问题，AMH 水平就可以替代更昂贵和更难获得的超声在 PCOS 诊断中的应用。
